Owkin Unveils Ai-driven Oncology And Immunology Pipeline, In-licenses Best-in-class Asset Okn4395

By Author: Orson Amiri
Total Articles: 377
Comment this article

Owkin, the first end-to-end TechBio unicorn, uses causal AI to revolutionize precision drug discovery and diagnostics. Recently, it announced an oncology and immunology drug pipeline after licensing OKN4395, a dual inhibitor of prostanoid receptors EP2 and EP4, from Idorsia. Owkin's AI-driven pipeline leverages multimodal patient data from 61 research centers and integrates spatial multiomics data via MOSAIC, the largest dataset of its kind, to capture tumor microenvironments. With extensive expertise in T-cell connectivity and AI drug discovery, Owkin aims to address critical challenges in precision medicine.

OKN4395, developed over 10 years by Idorsia, is positioned as a best-in-class dual inhibitor. Owkin’s AI engines, utilizing rich multimodal patient data, identified actionable biomarkers and optimal cancer indications for OKN4395. This approach aims to enhance clinical trial success and patient outcomes by integrating AI with traditional methods. Owkin's strategy includes building an external control arm for phase 1B trials and refining trial criteria using AI insights. With over $300 million in funding and partnerships with leading biopharma companies, Owkin is poised to expand its innovative pipeline in oncology, immunology, and inflammation.

Read More - https://www.techdogs.com/tech-news/business-wire/owkin-unveils-ai-driven-oncology-and-immunology-pipeline-in-licenses-best-in-class-asset-okn4395